12. Rod s-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Ver- sus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implanta- tion) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357 65. 13. Zuo W, Yang M, He Y, et al. Single or dual antiplatelet therapy after trans- catheter aortic valve replacement: an updated systemic review and meta- analysis. J Thorac Dis. 2019;11:959 68. 14. Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implanta- tion. Am J Cardiol. 2018;122:310 5. 15. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111 9. 16. Colli A, Mestres CA, Castella M, et al. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16:667 71. 17. Aramendi JI, Mestres C-A, Martinez-Le n J, et al. Triflusal versus oral an- ticoagulation for primary prevention of thromboembolism after biopros- thetic valve replacement (TRAC): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005;27:854 60. 18. Nu ez L, Gil Aguado M, Larrea JL, et al. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg. 1984;37:84 7. 19. Tiede DJ, Nishimura RA, Gastineau DA, et al. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc. 1998;73:665 80. 20. M rie C, K ber L, Skov Olsen P, et al. Association of warfarin ther- apy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118 25. 21. Russo A, Grigioni F, Avierinos J-F, et al. 